Background and Objectives：Time-phasic development of nitrate tolerance in cardiovascular diseases is very important because it can contribute to the advent of blunted vasodilation or rebound ischemia even during continuous NTG treatment. In such a condition, we should change the therapeutic regimen of nitrate treatment to prevent the worsening of symptoms. Materials and Methods：We created a nitrate-tolerant rat model using an osmotic minipump, and we examined the hemodynamic response to bolus NTG infusion in vivo. We checked the phosphodiesterase (PDE)1A1 mRNA and protein level by relative quantitative RT-PCR and western blot analysis. We used 8-cpt-cGMP for investigating the development of a time-phasic nitrate tolerance mechanism after nitrate infusion. Results：NTG-treated rats revealed a significant decrease in NTG-induced MAP drop (nitrate tolerance) from 1-day and this continued to the third day. The mRNA and protein levels of PDE1A1 similarly increased during these periods. Conclusion：This study revealed the development of time-phasic nitrate tolerance from the the aspects of in vivo hemodynamic responses and PDE 1A1 gene expression, and our work supports the need for further investigation to come up with a different therapeutic strategy and new drugs. (Korean
Introduction
Organic nitrates have been used for rapid relief of angina pectoris for over 100 years. The major action of organic nitrates is to decrease the VSMC tone that leads to dilation of the peripheral and coronary arteries, as well as dilation of the peripheral veins. 1) Within the VSMCs, it is recognized that organic nitrates (RONO 2 ) are converted to short-lived S-nitrosothiols (RSNO), and they then activate guanylate cyclase for stimulating cGMP formation. 2) 3) cGMP leads to vasodilation by decreasing intracellular Ca 2+ via the reuptake of Ca
2+
by the sarcoplasmic reticulum, and also by reducing the cell permeability to extracellular Ca 2+ . 4) The endogenous vasodilator released from the vascular endothelium, endotheliumderived relaxing factor (EDRF or NO), also activates guanylate cyclase. The fact that nitrates may have a role as a physiological substitute for EDRF has led to a revival of interest in organic nitrates for the treatment of angina. However, the long-term therapeutic effect of nitrates is limited by nitrate tolerance. The sustained administration of organic nitrates has long been recognized to result in the rapid development of tolerance to their anti-anginal and hemodynamic effects in both human and experimental animals (nitrate tolerance). [5] [6] [7] The basis for this nitrate tolerance is still not completely understood, but various mechanisms have been proposed to explain this phenomenon. These mechanisms are 1) impaired nitrate biotransformation, 8) 2) intracellular sulfhydryl group depletion, 9) 3) neurohumoral counter-regulation, 10) 4) overproduction of ROS, 11) /CaM-stimulated PDE (PDE-1A1).
13)
As a clinical concern, the time point in the development of nitrate tolerance for angina pectoris patients is very important because it can contribute to the development of blunted vasodilation or rebound ischemia even during continuous NTG administration, 18) and in such a condition the physician should change the therapeutic regimen of nitrate to prevent rebound angina. The present study investigated the time phasic development of nitrate tolerance in relation to the in vivo hemodynamic responses and PDE 1A1 gene expression.
Materials and Methods

Development of nitrate tolerance in vivo
Male Sprague-Dawley rats (Charles River Labs, 250 g to 300 g each) were anesthetized with ketamine 40 mg/kg, xylazine 0.5 mg/kg and acepromazine 5 mg/kg i.p. plus 1/3 the loading dose as needed. An osmotic minipump (model 2ML1:
Alza Corp) filled with either NTG (Zeneca Inc., Wilmington, DE, n=16) or vehicle (propylene glycol, n=6) was subcutaneously implanted at the dorsum of the neck. NTG was then infused at an average rate of 10 μg/kg/min for 1, 2 and 3 days.
At the end of each infusion period, the animals were sacrificed and dissected, and their thoracic aortas were taken and snapfrozen in liquid nitrogen after removal of the adventitia, and the aortas were then stored at -80℃ until use.
Hemodynamic responses to subsequent nitroglycerin bolus infusion
To assess for nitrate tolerance, the hypotensive effect of 
Quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Tissue RNA was extracted from the aortas using a Total RNA Isolation Kit (Ambion) based on manufactured protocol.
First strand cDNA was synthesized from 5 μg of total RNA by using random primers with the SuperScript Preamplification System (GIBCO BRL) according to manufacture's protocol. Quantitative RT-PCR was performed with 18s rRNA as an internal control using Ambion's competimer technology.
PDE1A1 specific primers (sense 5'-AAGATGACTGGAG-GGATCTTCG-3', antisense 5'-GAAAATGGAAGCCCTA-ATTCAGC-3') was used to generate a 281-bp PCR product for PDE1A1. The PCR products were then run on a 2% agarose gel, stained with ethidium bromide and quantified using image analysis software (NIH Image 1.60) (Fig. 2) .
Western blot analysis
PDE1A1 protein levels were determined by Western blot analysis. Tissue extracts were prepared as above. The tissue extract was centrifuged at 1000 g for 10 min at 4℃ to remove the cell debris. The supernatant was boiled in 1X sample buffer for 5 minutes, then loaded onto a SDS-polyacrylamide gel and electrophoresed. The separated proteins were transferred onto nitrocellulose membranes and next immunostained with PDE1-specific antibody (donated by University of Washington, Seattle, US). The immunoreactivity was detected by enhanced chemiluminescence using HRP-conjugated goat anti-rabbit IgG and a HRP-luminescent substrate mixture.
VSMC culture
Rat aortic VSMCs were isolated from 200-250 g male
Harlan Sprague-Dawley rats and they were maintained in 10% bovine calf serum (BCS) with Dulbecco's modified Eagle's medium as described previously 21. The rat aortic VSMCs (passages 7 to 12) at 70% confluence in 100 mm dishes were growth-arrested by incubation in 0.1% BCS DMEM for 48 hours prior to the indicated drug treatment.
The effects of cGMP on PDE1A1 gene expression in rat aortic
VSMCs
We measured the PDE1A1 mRNA levels in rat aortas treated with cGMP analogue (8-chrolophenylthio(cpt)-cGMP)
at the the indicated time. Rat aortic VSMCs were cultured and exposed to 8-cpt-cGMP (25 uM) for 0, 24, 48 and 72 hours.
The total RNA was extracted and the PDE1A1 mRNA levels were assayed by quantitative RT-PCR as described above.
Statistical analysis
One-way or 2-way ANOVA was used to compare differences between the treatment means, and the differences were expressed as means±SD. After ANOVA, comparison of 2 populations was made by Students unpaired t-test. p<0.05
were considered as statistically significant.
Results
Induction of in vivo tolerance
There was no significant difference of the baseline MAP between the control group and the NTG-pretreated group (104.3±3.9 vs. 100.8±4.1 mmHg, respectively) ( Table 1) .
For the control rats, acute NTG challenges caused dose-dependent decreases in the MAP ranging from 15.7±2.3% to 37.6±1.8% (Fig. 1) . The NTG-treatment group revealed sig- The hydralazine induced decrease in MAP (1 mg/kg, bolus)
was not different for both groups ( Table 1 ), indicating that the NO-independent vasodilation was similar in both groups.
The mRNA & protein level of PDE1A1 Is increased in nitratetolerant rats aorta
To determine the mRNA levels of PDE1A1 for each of the treatment periods, quantitative RT-PCR using PDE1A1 specific primers was performed (Fig. 2) . PDE1A1 mRNA levels in rat aorta of NTG-treated group according to the time periods were increased by 1.9±0.2, 2.0±0.3 and 2.4±0.2 fold, respectively, compared to the values of the control group (Fig. 3A) . The PDE1A1 protein level was also increased about 2-2.3 fold in the tolerant vessels at the similar periods (Fig. 3B) .
8-cpt-cGMP upregulates PDE1A1 mRNA gene expression
The cGMP analogue (8-cpt-cGMP, 25 uM) increased PDE1A1 mRNA by 2.0-2.1 fold, suggesting that the chronic cGMP increase stimulated by NTG treatment induced the PDE1A1 gene expression, and this protein subsequently hydrolyzes the cGMP. These findings suggest that the upregulation of PDE1A1 (and the decreased cGMP) is an important mechanism for the development of nitrate tolerance (Fig. 4) .
Discussion
Organic nitrates have been safely used as vasodilators for more than 100 years for the treatment of hypertension, ischemic heart disease and heart failure. Unfortunately, the therapeutic effect of nitrates is limited by the rapid development of tolerance (nitrate tolerance). Nitrate tolerance has been documented as the significant blunting of the hypotensive, vasodilatory capacity and also the supersensitivity to vasoconstrictors, which leads to vasoconstriction.
The present study supports the results of a previous study that in vivo NTG treatment of rats induces nitrate tolerance and this is caused by the increase of PDE1A1 gene expression.
13) The upregulation of PDE1A1 provided a new mechanism to explain, in part, the decreased sensitivity of the vasculature to NTG and the enhanced vasoconstriction observed in response to chronic NTG treatment; in addition, it Our previous study 13) suggested a new mechanism, that the induction of PDE1A1 activity would lead to an increased sensitivity of vasoconstrictors via the attenuation of cGMP accumulation in the nitrate tolerant vessels.
Time-phasic development of nitrate tolerance
Stewart et al 24) first described nitrate tolerance to the antihypertensive effect of NTG despite a 160-fold dose increase.
Many studies have revealed that nitrate tolerance effect on heart rate and blood pressure occurred within several hours to several days. that has gained acceptance is a nitrate free interval. However, by using intermittent therapy, the increased frequency of anginal attacks (termed rebound angina) has been observed. 34) In some cases, the rebound phenomenon can be a serious problem and may even result in sudden cardiac death. 35) This rebound effect is believed to be associated with the increased sensitivity to vasoconstrictors in the nitrate-treated vessels. 36) From the results of our study we should consider using other therapeutic strategies to prevent or modify nitrate tolerance such as intermittent dosing, and we should also further investigate possible new drugs such as PDE1A1-specific inhibitors.
Study limitations
This in vivo study was not performed for earlier time periods, like for 6 to 12 hours of NTG treatment, and it was also not performed for longer periods of more than 3 days.
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